200 related articles for article (PubMed ID: 24756790)
1. Sorafenib: targeting multiple tyrosine kinases in cancer.
Hasskarl J
Recent Results Cancer Res; 2014; 201():145-64. PubMed ID: 24756790
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib.
Hasskarl J
Recent Results Cancer Res; 2010; 184():61-70. PubMed ID: 20072831
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib and thyroid cancer.
Fallahi P; Ferrari SM; Santini F; Corrado A; Materazzi G; Ulisse S; Miccoli P; Antonelli A
BioDrugs; 2013 Dec; 27(6):615-28. PubMed ID: 23818056
[TBL] [Abstract][Full Text] [Related]
4. Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option.
Smolle E; Taucher V; Petru E; Haybaeck J
Anticancer Res; 2014 Apr; 34(4):1519-30. PubMed ID: 24692678
[TBL] [Abstract][Full Text] [Related]
5. The adverse effects of sorafenib in patients with advanced cancers.
Li Y; Gao ZH; Qu XJ
Basic Clin Pharmacol Toxicol; 2015 Mar; 116(3):216-21. PubMed ID: 25495944
[TBL] [Abstract][Full Text] [Related]
6. Aggressive thyroid cancer: targeted therapy with sorafenib.
Corrado A; Ferrari SM; Politti U; Mazzi V; Miccoli M; Materazzi G; Antonelli A; Ulisse S; Fallahi P; Miccoli P
Minerva Endocrinol; 2017 Mar; 42(1):64-76. PubMed ID: 26112458
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib in patients with refractory or recurrent multiple myeloma.
Yordanova A; Hose D; Neben K; Witzens-Harig M; Gütgemann I; Raab MS; Moehler T; Goldschmidt H; Schmidt-Wolf IG
Hematol Oncol; 2013 Dec; 31(4):197-200. PubMed ID: 23494836
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib for ovarian cancer.
Leone Roberti Maggiore U; Valenzano Menada M; Venturini PL; Ferrero S
Expert Opin Investig Drugs; 2013 Aug; 22(8):1049-62. PubMed ID: 23675696
[TBL] [Abstract][Full Text] [Related]
9. Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma.
Peng S; Wang Y; Peng H; Chen D; Shen S; Peng B; Chen M; Lencioni R; Kuang M
Hepatology; 2014 Oct; 60(4):1264-77. PubMed ID: 24849467
[TBL] [Abstract][Full Text] [Related]
10. Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-like tyrosine kinase-3 internal tandem duplication positive acute myeloid leukemia.
Gill H; Man CH; Ip AH; Choi WW; Chow HC; Kwong YL; Leung AY
Haematologica; 2015 Jul; 100(7):e250-3. PubMed ID: 25820334
[No Abstract] [Full Text] [Related]
11. Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.
Horwitz E; Stein I; Andreozzi M; Nemeth J; Shoham A; Pappo O; Schweitzer N; Tornillo L; Kanarek N; Quagliata L; Zreik F; Porat RM; Finkelstein R; Reuter H; Koschny R; Ganten T; Mogler C; Shibolet O; Hess J; Breuhahn K; Grunewald M; Schirmacher P; Vogel A; Terracciano L; Angel P; Ben-Neriah Y; Pikarsky E
Cancer Discov; 2014 Jun; 4(6):730-43. PubMed ID: 24687604
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib for the treatment of multiple myeloma.
Gentile M; Martino M; Recchia AG; Vigna E; Morabito L; Morabito F
Expert Opin Investig Drugs; 2016 Jun; 25(6):743-9. PubMed ID: 26998658
[TBL] [Abstract][Full Text] [Related]
13. Spontaneous regression of metastatic papillary renal cell cancer after cessation of treatment with sorafenib.
Grenader T; Rosenbaum E; Zilber S; Bogot N; Shavit L
Clin Genitourin Cancer; 2013 Jun; 11(2):201-3. PubMed ID: 23266054
[No Abstract] [Full Text] [Related]
14. The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications.
Delire B; Stärkel P
Eur J Clin Invest; 2015 Jun; 45(6):609-23. PubMed ID: 25832714
[TBL] [Abstract][Full Text] [Related]
15. Discovery of potent, orally active compounds of tyrosine kinase and serine/threonine-protein kinase inhibitor with anti-tumor activity in preclinical assays.
Qiu YQ; Zhou J; Kang XS; Shen-Tu JZ; Ding LM; Tan FL; Guo J; Li LJ
Afr J Tradit Complement Altern Med; 2012; 9(3):431-9. PubMed ID: 23983378
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib in renal cell carcinoma.
Davoudi ET; bin-Noordin MI; Javar HA; Kadivar A; Sabeti B
Pak J Pharm Sci; 2014 Jan; 27(1):203-8. PubMed ID: 24374450
[TBL] [Abstract][Full Text] [Related]
17. Partial response of angiosarcoma of the scalp to sorafenib: association with decreased expression of vascular endothelial growth factors and their receptors.
Tamiya H; Kamo R; Kumei A; Yanagihara S; Ishii M; Kobayashi H
Clin Exp Dermatol; 2012 Oct; 37(7):749-52. PubMed ID: 22369131
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib (Nexavar) for thyroid cancer.
Med Lett Drugs Ther; 2014 May; 56(1443):43-4. PubMed ID: 24869715
[No Abstract] [Full Text] [Related]
19. Regorafenib.
Ettrich TJ; Seufferlein T
Recent Results Cancer Res; 2014; 201():185-96. PubMed ID: 24756792
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Sorafenib for Advanced Hepatocellular Carcinoma and Prognostic Factors.
Li J; Wang L; Cong N; Shi C; Bu W; Song J; Chen H
Hepatogastroenterology; 2014 Jun; 61(132):954-7. PubMed ID: 26158148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]